loading page

Inotuzumab ozogamicin is an effective treatment for CD22-positive acute undifferentiated leukemia: A case report
  • +12
  • Ryo Akazawa,
  • Itaru Kato,
  • Hirohito Kubota,
  • Kiyotaka Isobe,
  • Hiroaki Masuno,
  • Masamitsu Mikami,
  • Mitsutaka Shiota,
  • Kagehiro Kozuki,
  • Naoko Kawabata,
  • Kuniaki Tanaka,
  • Satoshi Saida,
  • Katsutsugu Umeda,
  • Hidefumi Hiramatsu,
  • Souichi Adachi,
  • Junko Takita
Ryo Akazawa
Graduate School of Medicine, Kyoto University

Corresponding Author:akzwryo@kuhp.kyoto-u.ac.jp

Author Profile
Itaru Kato
Graduate School of Medicine, Kyoto University
Author Profile
Hirohito Kubota
Graduate School of Medicine, Kyoto University
Author Profile
Kiyotaka Isobe
Graduate School of Medicine, Kyoto University
Author Profile
Hiroaki Masuno
Kitano Hospital, The Tazuke Kofukai, Medical Research Institute
Author Profile
Masamitsu Mikami
Kitano Hospital, The Tazuke Kofukai, Medical Research Institute
Author Profile
Mitsutaka Shiota
Kitano Hospital, The Tazuke Kofukai, Medical Research Institute
Author Profile
Kagehiro Kozuki
Graduate School of Medicine, Kyoto University
Author Profile
Naoko Kawabata
Graduate School of Medicine, Kyoto University
Author Profile
Kuniaki Tanaka
Graduate School of Medicine, Kyoto University
Author Profile
Satoshi Saida
Graduate School of Medicine Kyoto University
Author Profile
Katsutsugu Umeda
Graduate School of Medicine, Kyoto University
Author Profile
Hidefumi Hiramatsu
Graduate School of Medicine, Kyoto University
Author Profile
Souichi Adachi
Graduate School of Medicine, Kyoto University
Author Profile
Junko Takita
Graduate School of Medicine, Kyoto University
Author Profile

Abstract

Acute undifferentiated leukemia (AUL) is a rare subtype of leukemia that expresses no lineage-specific markers; no optimal treatment for AUL has been established. Here, we report a 16-year-old female with CD22-positive refractory AUL who responded well to inotuzumab ozogamicin (InO). Minimal residual disease negativity was achieved using InO, followed by HLA-mismatched unrelated bone marrow transplantation (BMT). Although grade II veno-occlusive disease/sinusoidal obstruction syndrome occurred, it improved immediately. She remained disease-free at 10 months post-BMT, without severe complications (grade III–IV). This case demonstrates the feasibility of a treatment strategy using InO against CD22-positive AUL.